Cal-X Stars Business Accelerator Inc. DBA Leonhardt’s Launchpads Annual Shareholder Meeting Notice May 5th 2017

Second Notice of Annual Shareholders Meeting
Cal-X Stars Business Accelerator Inc. a California Corporation

Notice is hereby given that the annual general meeting of the shareholders of all classes of stock of Cal-X Stars Business Accelerator Inc. will be held at the company’s headquarters at 2000 Main Street, Santa Monica CA 90405 on Friday May 5th 2017 at 3pm PST for the purpose of:

1. Receiving and considering the annual report and financial statements for the year ended Dec. 31st 2015 and report of board assigned task force committees including any audits thereon;
2. Electing directors;
3. Executive compensation approval; stock option plans for advisors consultants and employees approval; shareholder loans to company & promissory notes review and approval;
4. Major material supply and distribution agreements approval;
5. Re-appointing corporate accountant and legal counsel and;
6. Transacting such further and other business as may properly come before the meeting or any adjournment thereof including 2016 portfolio progress review and forward major goals.
Here is a link to a table of the Leonhardt Ventures’s Cal-X Stars Business Accelerator Inc. 2016 Portfolio Class of 26 Regenerative Medtech and 4 Regenerative Economy Startups with current valuations and target goals valuations for the end of 2019 – which includes hyperlinks to all the individual startup web sites –

An advance notice was emailed to all shareholders of record April 5th, 2017 and again on April 19th, 2017 on behalf of the board of directors.
Shareholders not able to attend in person may call into this line at 3pm PST May 5th, 2017 to participate in the meeting.
· Dial-in Number: (712) 775-7031
· Access Code: 405-822-417

Cal-X Stars Business Accelerator, Inc. DBA Leonhardt’s Launchpads Board of Directors
Executive Chairman of the Board: Howard J. Leonhardt – eSigned – Howard J. Leonhardt
Secretary & Treasurer: Sofia Yepes
Voting Board Directors: Jeremy Koff, Tricia Nordy, Jeff Donofrio, Dr. Mark Cunningham, Alex Richardson
Committees: Compensation = Chair Jeremy Koff, Ken Evans, Jeff Donofrio
Audit = Brittany Brown CPA, Jeff Donofrio
Legal Counsel = Bruce Methven Corporate Securities, Allen Turner Patents
Board Meeting Attending Non-Voting Advisors (some may attend by Skype): Ken Evans, Paul Norman, Walter Grieves, Laurelle Johnson, Brittany Brown CPA, Bruce Methven Corporate Attorney, Allen Turner Patent Attorney, Kevin Arnal Chief Engineer Biomerics Advanced Catheter, Richard Koffler, Michael Newton, Derek Kahn, Dr. King Liu, Dr. Patrick Johnson, Dr. Santosh Kesari, Tom Newman, Henk Abbink, Joel Hirsch, Dr. Leslie Miller our Chief Medical Officer
Updates will be provided on these portfolio startups and Licensable Technology Platforms (LTPs) including current ownership cap tables and valuation analysis:

Regenerative Medtech Portfolio (26)

1. BioLeonhardt MyoStim – heart and limb regeneration – 2012
2. CerebraCell – brain regeneration – 2015
3. Stem Cell Bra – breast regeneration – 2013
4. EyeCell – eye regeneration – 2015
5. AortaCell – aorta regeneration – 2012
6. BioPace – biological pacemaker regeneration – 2012
7. Valvublator – heart valve regeneration – 2012
8. CoroStim & VibroCell – vibrational energy to prevent clots, plaque & calcification – 2012
9. HeartScore – genomics, high fidelity monitoring and bioelectric based heart failure and stroke management – 2013
10. DentaCell – dental gum regeneration and tooth pulp (stem cells) storage – 2014
11. OrthodontiCell – designed to cut in half dental brace and aligner wearing time and freeze teeth positions – 2015
12. PancreaCell – pancreas regeneration – 2015
13. RegenaLung & RegenaLung COPD – lung regeneration & COPD treatment – 2015
14. CancerCell – bioelectric cancer tumor treatment regeneration – 2016
15. EndoCell – artery regeneration – 2013
16. MyoStim ED – erectile dysfunction treatment – 2015
17. MyoStim Skin & SkinCell Stimulator – skin regeneration – 2015
18. MyoStim Peripheral – limb blood flow improvement & diabetic foot ulcer treatment – 2011
19. BladderCell – 2016
20. Second Heart Assist, Inc. – circulating assist pumps – 2016
21. HairCell – hair regeneration – 2016
22. Leonhardt-Wetling* Peripheral – wireless diabetic foot ulcer treatment – 2014
23. BioLeonhardt Whole Body Regeneration – Whole body regeneration – 2015
24. LiverCell – liver regeneration – 2016
25. KidneyCell – kidney regeneration – 2016
26. EarCell – ear hearing regeneration – 2016
*Note – Leonhardt-Wetling JV agreement for wireless microcurrent technology is still pending finalization at time of this notice. If the agreement is not finalized within the next 90 days the board proposes to shareholders adding MucosaCell (sub mucosa regeneration) to the portfolio and dropping Wetling.
Regenerative Economy Portfolio (4)

1. The California Stock Exchange TM – social good stock exchange in development and crowdfunding services – 2011
a. Cal-X Crowdfund Connect – crowdfunding campaign bulding assistance – 2012
b. Cal-X 30 Social Good Impact Fund powered by Motif Investing – 30 curated social good impact stocks – 2015
c. Cal-X Microloans – in collaboration with ZimpleMoney – crowd sourced loans – 2014
d. Cal-X Funders Syndicate -Special Purpose Vehicles and Simple Advance Future Equity Agreements – 2014
e. CalXports – export sales campaign building assistance for California startups – 2013
g. PRETAIL Fashion – pre-selling fashion designs and crowdsourcing most popular designs to go to production – 2015

2. Leonhardt Incubators & Accelerators
a. Cal-X Stars Business Accelerator Inc. – regenerative medtech and economy startup & innovation accelerator – 2013
b. CalXelerator – 108 day startup accelerator/incubator for social good impact companies – 2013
c. SciAccelerator – 108 day startup accelerator for science based tech startups – 2016
d. Leonhardt’s Launchpads NorCal @ University of Northern California Science Technology Innovation Center (UNC STIC) – life science startup incubator – 2007
e. Leonhardt’s Launchpads Utah, Inc. – innovation accelerator focused on organ regneration and recovery – 2015
f. LABioHub – resources for Los Angeles area life science cos. – 2015
g. Startup California – resources for California startups – 2011

3. Kindheart Lionheart Media & Publishing Co. – Social good media- 2006
a. The Kindheart Lionheart TV Network – social good impact online television network – 2014
> California Love TV Program – in house original TV program about new love – 2014
> Love Dialogues TV Program – in house original candid no frills conversations on the topice of love – 2015
> Love Roller Coaster TV Program – original love themed sitcom – 2015
> LIONS DEN Startup Pitch TV Program – in house original online crowdfunding based startup pitch program – 2015
> The Kindheart Lionheart TV and Radio Program – social good profiles of compassion and courage radio and TV show – 2013
b. Kindheart Lionheart Book Club – social good impact book club – 2006
c. Kindheart Lionheart Startup Media Support Services – startup media support including video and animation production – 2014
d. Kindheart Lionheart Adventures – social good charitable vacations and charitable foundation fund raising tools – 2001
e. Radio Veronica USA Radio Santa Monica USA – online radio station that permits listeners to buy into publishing rights of songs – 2010
f. Wine Country Baseball – Sonoma and Napa based summer amateur baseball league to raise funds for local causes and parks – 2009
g. Dolphin Smiles: The Legend of Kindheart Lionheart – (under development with help of UCLA writing program) – in house original story of a person dedicated to social good change reincarnated as a dolphin – 1997

4. Leonhardt Food & Beverage
a. Lucille’s American Cafe’s* (50% worldiwde franchise, trademark and recipes rights) – comfort food restaurants – 1996
b. Food Trikes & Scooters – mini electric food trucks with crowdfunding and micro loans to finance – 2013
c. California Wine Financing – loans to small California family wineries to bridge cash flow gaps – 2008
d. Lionheart Cider* (distribution western states) – Minnesota based cider co. – Leonhardt has option for western states distribution – 2014
e. Leonhardt Oak Aged Beer (development stage) – sour mash beer aged in former oak wine barrels for a unique taste – 2015

Refer to Investor Relations Page for Risks and Warnings Within Our Private Placement Memorandum. Refer to Latest Newsletters for Updates. and
The Cal-X Stars Business Accelerator, Inc. DBA Leonhardt’s Launchpads business model is to accelerate each startup through to first-in-man study results for the regenerative medtech portfolio and through to acquisition of 10,000 customers/subscribers for the regenerative economy startups and then dutch auction them off to the best strategic partner preferrably with 3% royalty on net sales forward.
Securities offered under Rule 506(c) may be purchased only by accredited investors = persons with > 1 million in assets excluding their home and vehicles or whom have income > $200,000 the past two years consecutively or > $300,000 income as a couple. Accreditation status must be verified via documentation of credible third parties in a position to provide accurate verification. Investors in this offering should have experience in making early stage investments.
Cal-X Stars Business Accelerator Inc. develops early stage innovations and startups. By nature the risk is very high for these type of investments. Any investor should be fully prepared without reserve to lose all their investment. Our high focus on developing implantable devices and biologics for treating heart failure add exceptionally higher levels of risk as the products require multiple stages of clinical trials costing many millions of dollars and require high intellectual property protection to succeed commercially. The patent landscape in these areas of participation are wrought with potential for litigation. A high number of clinical trials in the heart failure space fail to prove greater safety and efficacy compared to currently available choices. A high number of early seed stage innovations fail to ever make it to market and even a smaller number become commercial successes. This type of investment is NOT appropriate for nest egg savings.

• The securities are being offered in reliance on an exemption from the registration requirements of the 150Securities Act and are not required to comply with specific disclosure requirements under the Securities Act; the Commission has not passed upon the merits of or given its approval to the securities the terms of the offering or the accuracy or completeness of any offering materials; the securities are subject to legal restrictions on transfer and resale and investors should not assume they will be able to resell their securities; and investing in securitiesinvolves risk and purchasers should be able to bear the loss of the entire investment. Private funds would be required to include a legend informing investors that the funds are not subject to the protections of the Investment Company Act.

Accuracy of Information Disclaimer: Representations and warranties – although we fully believe that our executive summaries newsletters websites and other written materials and videos accurately represent a true and accurate general high level picture of our activities history and progress – which is developing about 26 early stage un-proven cardiovascular life innovations and 4 early stage startup social good impact innovations (including new media social good projects) in an accelerator/incubator – we acknowledge that working with a very small core staff covering many thousands of pages of written materials across over 50 web sites with over 4000 sub-pages that we are highly prone to small errors outdated materials and a certain level on inaccuracy and inconsistencies even while fully striving for the utmost accuracy. Across the 30 innovations and over 2000 working partnerships being developed there are changes and events that occur almost daily. We do our best to keep all websites and published materials fully up to date but recognize and make clear it is nearly impossible for our small staff to keep all materials on all web sites 100% up to date despite our best efforts to do so. Investors have the advantage with us that our small staff operates with a very low overhead but the offset disadvantage is that we do not have on hand the staffing to handle all the constant updates and proofreads needed to keep thousands of pages of materials up to date and 100% accurate 100% of the time. If you have ANY direct question about any published item of material interest to you – JUST ASK for clarification by emailing direct Howard Leonhardt at or calling our office DIRECT GOOGLE VOICE MAIL LINE at (424) 291-2133. We will strive to provide a clarification or update to you promptly.

Most recent press releases:

Leonhardt’s Launchpads Chooses Biomerics To Provide Contract Manufacturing and Engineering Design Services For Medical Devices
Leonhardt Ventures to Enter Into Worldwide Strategic Collaboration With Neuro Code Tech Holdings for Customized Bioelectric Cancer Treatments
Leonhardt Ventures to Present Heart and Heart Valve Regeneration Technologies at Cardiovascular Research Technologies (CRT) Meeting February 21st in D.C.
Leonhardt’s Launchpads Expands Patent Estate with Option to Exclusive License Agreement With Caltech
Leonhardt and Genovese file Patent for Bioelectric Controlled Expression of PDGF a Powerful Organ Regeneration Cytokine

Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc., 2000 Main Street, Unit 333, Santa Monica, CA 90405 – +

Leonhardt’s Launchpads Utah, Inc. 370 S, 300 E, Salt Lake City, UT 84111
Research Lab @ 2500 S State St. #224, Salt Lake City, UT 84115
Cental Google Voice Mail Telephone Number all Units: (424) 291-2133

Leonhardt’s Launchpads by Cal-X Stars, 2000 Main Street, Unit 333, Santa Monica, CA 90405 – +

Leonhardt’s Launchpads Utah, Inc. 370 S, 300 E, Salt Lake City, UT 84111
Research Lab @ 2500 S State St. #224, Salt Lake City, UT 84115

Leonhardt’s Launchpads Expands Patent Estate with Option to Exclusive License Agreement With Caltech

Press Release – March 22nd, 2017 – Santa Monica, CA, Pasadena, CA, Salt Lake City, Utah.–(PRBUZZ)— Leonhardt’s Launchpads, a Santa Monica, California and Salt Lake City, Utah based innovation accelerator focused on organ regeneration and recovery technologies announced today that it has significantly expanded its patent portfolio. Leonhardt’s Launchpads via this agreement obtained an option leading to an exclusive license to a series of patents and patents pending held by the California Institute of Technology (Caltech) in Pasadena, California in the field of wireless powered and minitature stent based circulatory assist pumps.

“The Caltech estate of patents combined with our own patent portfolio provides Leonhardt’s Launchpads, and our incubating startup Second Heart Assist, Inc., with a pathway to very strong patent protection in the wireless powered and stent based circulatory assist pump market. These patents serve as an important foundation for us as we continue to grow the business and develop our product pipeline” states Jeff Donofrio, President of Second Heart Assist, Inc.

The patent estate option exclusively licensed from Caltech includes these pioneering patents as well as many more other continuations in part and additional patent claims pending:

U.S. 7,998,190 8/16/2011 Intravascular Miniature Stent Pump
U.S. 7,163,385 1/16/2007 Hydroimpedance Pump
U.S .8,092,365 1/10/2012 Resonant Multilayer Impedance Pump
U.S .7,883,325 02/08/2011 Helically Actuated Positive-Displacement Pump and Method
Leonhardt’s Launchpads has in-turn exclusively licensed this option and patents in exchange for 9% seed stage equity and $50,000 cash (to be paid in increments) to Second Heart Assist, Inc. (Second Heart) a Utah C corporation incubating in Leonhardt’s Launchpads Utah, Inc. innovation and startup accelerator in Salt Lake City as well as its Santa Monica based accelerator. The Caltech exclusive option licensed patents cover technologies designed to develop a wireless powered circulatory assist pump placed within the aorta of a patient. The patent claims cover a product designed to reduce risk of hemolysis, thrombosis, mechanical breakdown and infection associated with previously developed circulatory assist devices as well as easing placement. Second Heart intends to apply this to the treatment of heart failure, reducing risk in high risk PCI, cardiogenic shock recovery, kidney protection and limb salvage. One of the primary expected uses of the product is to elminate excess fluid buildup from patients suffering of heart failure more quickly than other alternatives. The Second Heart team has aspirations to bring to market the first wireless powered circulatory assist pump that has the option for both continuous and pulsatile flow. The Leonhardt led team has developed a wirelesss harmonic vibration technology which it hopes to prove out in studies to reduce risk associated with thrombosis (blood clotting), often a problem with previous chronic long term use circulatory assist devices.

Second Heart Assist, Inc. also plans to develop this technology to be supportive to heart regeneration working in partnership with BioLeonhardt another early stage Leonhardt’s Launchpads startup that has developed a bioelectric stimulator (controls release of up to 13 regeneration promoting proteins) + re-fillable micro infusion pump + fifteen component heart regeneration stem cell/growth factor composition designed to regenerate hearts. This technology is currently under evaluation in pre-clinical studies at the University of Utah. The thought of combining the two technologies is that a heart may be easier to regenerate if its workload is reduced by a circulatory assist device and perfusion is improved.

“The Caltech patents provide us with pioneering technologies to potentially reduce hemolysis, thrombosis, infection and mechanical breakdowns found in other circulatory assist pumps. This is an exciting development for our organization.” states Howard J. Leonhardt, Founder, Executive Chairman & CEO of Leonhardt’s Launchpads and Second Heart Assist, Inc.

This option license leading to an exclusive patent license includes a provision for collaborative research between the Leonhardt led Second Heart team and Dr. Morteza Gharib’s (primary inventor of the series of patents) lab at Caltech. This Caltech Gharib lab has already built and tested a number of prototypes and has published some supporting data. The two research teams will work together to advance the technology to clinic.

About Leonhardt’s Launchpads:

Leonhardt’s Launchpads is an innovation accelerator focused on organ regeneration and recovery technologies with operations in California and Utah. Leonhardt’s Launchpads was formed by Leonhardt Ventures in 2008 in Northern California, opened up in Southern California in 2013 and in Utah in 2015. They currently are incubating 30 startups. Leonhardt Ventures was founded in 1982 (originally HJ Leonhardt & Co.). In the 1980’s the Leonhardt team led in patented cardiovascular balloon catheter development, in 1990’s stent grafts and percutaneous heart valves, since 2000 the focus has been on organ regeneration and recovery. Howard Leonhardt their founder has over 21 issued U.S. patents and a dozen more pending.

About Second Heart Assist, Inc:

Second Heart Assist, Inc. was formed in 2016 and incorporated in Utah as a C corporation in 2017. It is focused on developing circulatory assist devices with the primary application of helping heart failure patients recover –

Caution: This product has not yet been tested in clinical trials and is not yet proven to be safe or effective. This is an early stage unproven development.

Video animation of one model of circulatory assist pump within stent being developed by Second Heart Assist, Inc. team –

Leonhardt’s Launchpads Chooses Biomerics To Provide Contract Manufacturing and Engineering Design Services For Medical Devices

Press Release – March 14th, 2017 – (PRBUZZ) – Salt Lake City, Utah, Santa Monica, CA and Brooklyn Park, Minnesota – Today Leonhardt’s Launchpads announced it has selected Biomerics LLC Utah and Biomerics Advanced Catheter Minnesota as its primary source manufacturer for a number of medical devices it has patented and developed.

These devices include:

  • Second Heart Assist, Inc. aorta position circulatory assist pumps – both temporary on catheter and wireless chronic devices.
  • Electrical stimulation pacing and stem cell + growth factor infusion leads for Leonhardt’s full lineup of organ regeneration devices.
  • Valvublator catheter based device for decalcifying and regenerating heart valves.

This OEM contract includes;

  • rapid protyotype building and testing;
  • catheter design;
  • circulatory assist pump assemblies;
  • pacing lead and infusion catheter assemblies;
  • mechanical fabrication;
  • cGMP clinical manufacturing;
  • quality assurance;
  • packaging and arranging sterilization then shipping.

“With Leonhardt’s long standing record of major medical device innovations we are honored to be chosen as their primary OEM supplier,” remarked Steve Berhow, President of Biomerics Advanced Catheter. “At Biomerics Advanced Catheter, we’ve always taken pride in our ability to help customers propel their ideas forward. By design we are set up to serve clients, like Leonhardt, to better integrate their minimally invasive engineering technologies with large scale manufacturing solutions. I am excited about the potential to participate in potentially improving and saving lives of thousands maybe millions with Leonhardt’s breakthrough technologies and for the corresponding flow of continuous long term business for Biomerics Advanced Catheter.”

“This agreement highlights Biomerics’ commitment and presence in serving true medical innovators,” stated Travis Sessions, CEO of Biomerics, LLC. “We remain committed to providing next generation solutions to the cardiovascular, structural heart, cardiac rhythm management, electrophysiology, and neurovascular markets. Leonhardt’s Launchpads incredibly is developing innovations in ALL these areas. Our new agreement with Leonhardt is yet another step towards remaining at the forefront of design and manufacturing within these demanding market segments. That leadership position could be forged for years to come considering the depth of Leonhardt’s unprecedented innovation pipeline.”

“We set up operations in Utah in November 2015 because of the incredible infrastructure to support biomedical innovation. Biomerics is a perfect example. Earlier this month we visited their Advanced Catheter team in Minnesota, where Leonhardt Ventures began in 1982, and found their engineers to be amongst the best we have ever worked with in our history. We are highly impressed with their rapid prototyping capabilities served by unparalleled integrated operations extending from polymer design, proprietary non-thrombogenic coatings, high level extrusion, molding and complicated assembly. Their attention to detail and quality in both design and manufacturing makes them an ideal partner for us. We believe this is just the beginning of a long standing great working relationship.” stated Howard Leonhardt, Founder, Executive Chairman & CEO of Leonhardt’s Launchpads

Leonhardts’ Second Heart Assist device is expected to be the first percutaneous placed design that offers both pulsatile and continuous flow options and incorporates harmonic vibrational energy technology to reduce risk of thrombosis. The chronic support version is wirelessly powered. The Leonhardt team has entered an exclusive patent option license agreement with Caltech covering 4 issued U.S. patents and numerous others pending. The option licensed Caltech patent estate includes miniature stent pump designs and technologies designed to minimimize hemolysis, thrombosis, infection and mechanical breakdown associated with previous chronic use circulatory assist devices. The Second Heart Assist device was originally developed by the Leonhardt team to compliment their BioLeonhardt heart regeneration and MyoStim Peripheral limb salvage technologies.

Leonhardt Stent Pump from Calx Stars Business Accelerator on Vimeo.

About Biomerics:

Biomerics, LLC specializes in the design, development, and production of finished medical devices used in diagnostic and interventional procedures. Biomerics provides complete development and manufacturing solutions for customers in the cardiovascular, structural heart, cardiac rhythm management, electrophysiology, neurovascular, vascular access, and pain management markets. Headquartered in Salt Lake City, Biomerics has operations across three ISO-13485 compliant facilities. Biomerics has a 40,000 sq. ft. facility in Salt Lake City, Utah and a 52,000 sq. ft. new start of the art building in Brooklyn Park, Minnesota specializing in Advanced Catheters –

About Leonhardt’s Launchpads:

Leonhardt’s Launchpads is an innovation accelerator focused on organ regeneration and recovery technologies with operations in California and Utah. Leonhardt’s Launchpads was formed by Leonhardt Ventures in 2008 in Northern California, opened up in Southern California in 2013 and in Utah in 2015. They currently are incubating 30 startups. Leonhardt Ventures was founded in 1982 (originally HJ Leonhardt & Co.). In the 1980’s the Leonhardt team led in patented cardiovascular balloon catheter development, in 1990’s stent grafts and percutaneous heart valves, since 2000 the focus has been on organ regeneration. The team is most well known for dominant world leadership in stent grafts for repair of aortic aneurysms without surgery, one of the first patented percutaneous heart valves and completing the first non-surgical stem cell repair of a human heart in 2001. Howard Leonhardt their founder has over 21 issued U.S. patents and a dozen more pending.

Leonhardt Ventures to Enter Into Worldwide Strategic Collaboration With Neuro Code Tech Holdings for Customized Bioelectric Cancer Treatments


Collaboration will draw upon Leonhardt’s leading position in bioelectric stimulation controlled protein expression and Neuro Tech Holdings premier customized bioelectric read and write neuro code tumor treatment platform

CancerCell, a Leonhardt Ventures’ startup – see video – – incubating in the Leonhardt’s Launchpads Utah, Inc. innovation accelerator, a private licensable technology platform and team developing personalized bioelectric cancer therapies, announced today that it will enter into a worldwide strategic collaboration with Neuro CodeTech Holdings to develop, manufacture and commercialize novel bioelectric based, individualized bioelectric cancer therapies. The collaboration will combine Leonhardt’s leading bioelectric stimulation controlled protein expression portfolio and research program with Neuro Code Tech Holdings proprietary cancer neuro-code read and write technology platform, providing personalized medicine solution to shrinking cancer tumors, by stopping cell division, and starving them of blood supply. Together, the two companies will develop individually tailored cancer therapies against a broad range of cancers to potentially provide a new treatment paradigm for cancer patients.

CANCER_CELL from Calx Stars Business Accelerator on Vimeo.

The collaboration will focus on the development of bioelectric cancer tumor destruction therapies targeting the inactivation of a tumor’s ability to continue cell division based upon both Leonhardt’s and Neuro Code Tech Holdings individualized cancer therapy clinical platforms for the potential treatment of multiple cancers. With Neuro Tech Holdings patented technology a patient’s cancer tumor’s communication signals can be rapidly read utilizing next generation neural code reading technology to define a spectrum of unique mutation promoting signals that can be jammed and thus prevented from further cell division by a customized bioeleletric return signal. The Leonhardt bioelectric signal controlled protein expression technology can be used to activate release of a mRNA encoding selected neoepitope which can be manufactured for each individual tumor’s mutanome signature by a specific bioelectric signal, which can trigger an immune response highly specific to the tumor resulting in precisely targeted cancer cell death. The Leonhardt patented and patent pending technology platform includes signals for stopping cell division and halting blood supply to destroy a cancer tumor followed by over thirteen organ regeneration promoting signals and protein expressions to rebuild the organ after the cancer has been eliminated.

Initial clinical development will focus on combination studies targeted at shrinking brain, pancreas and breast cancer tumors. Under the terms of the agreement Leonhardt will pay Neuro Code Tech Holdings in installment payments as near-term and long-term milestones are met and the two companies will share ownership of the startups that receive exclusive licenses to commercialize the combined technologies.

The specific Neuro Code Tech Holdings LLC intellectual property to be utilized in this agreement includes U.S. patent 9,032,964, entitled “Method and system for processing cancer cell electrical signals for medical therapy.” According to the abstract, a scientific computer system with processor capable of recording, storing, and reprogramming the natural electrical signals of cancer cells as found in tumors of humans and animals. The reprogramming process is designed to create a confounding electrical signal for retransmission into a malignant tumor to damage or shut-down the cellular internal electrical communication system. Altering the electrical charge on the glycocalyx of the outer cell membrane is also part of the treatment by application of ions. The invention causes cancer cell death as a medical treatment using ultra-low voltage and amperage encoded signals which are reprogrammed from cancer cell communication signals.

Dr. Santosh Kesari, Neuro Scientist and Chief Scientific Advisor to CancerCell and CerebraCell, Leonhardt Ventures cos. commented: “We are delighted to collaborate with leading bioelectric personalized cancer therapy inventors such as Eleanor Schuler of Neuro Code Tech Holdings. Supported by its extensive bioelectric stimulation signal protein expression control understanding, the Leonhardt team has been building experience with its proprietary bioelectric driven therapies, often combined with stem cell based compositions, in a number of organ specific applications over nearly three decades. Combining Leonhardt’s broad proprietary capabilities in the design, formulation, manufacturing and clinical testing of combination therapy organ regeneration and controlled protein expression technologies with Neuro Code Tech Holdings’ eminent neural code read and write signaling expertise, will allow us, on a global scale, to drive forward the development of individualized therapies to market to not only treat and potentially stop a broad range of cancers but also to fully regenerate those same organs post cancer. No other research group we know of is offering this one two punch combination designed to help patients recover to a full quality of life.” Dr. Kesari is Chair and Professor, Department of Translational Neurosciences and Neurotherapeutics, Director, Neuro-oncology the Providence John Wayne Cancer Institute and Director of Neuro-Oncology at the Pacific Neuroscience Institute and Brain Tumor Center both in Santa Monica, California where CancerCell and CerebraCell expect to launch first-in-man clinical trials in the future –

Eleanor Schuler, CSO of Neuro Code Tech Holdings LLC added: “This alliance underpins Neuro Code Tech Holding’s strategy of collaborating with companies that are committed to developing truly disruptive therapies and its long term ambitions of bringing its patented inventions to clinics to begin helping people recover from the devastation of cancer. Our proprietary patented technology is the only one we know of that reads the communication signals within a tumor and customizes back an individualized therapy. No two cancer tumors are alike. To treat them you need a customized approach.”

“Unlike any medicine ever developed, virtually all cancer patients may potentially benefit from a custom built bioelectric cancer therapy followed by total organ regeneration,” said Luis Ortiz, Patent Counsel and President of Neuro Code Tech Holdings. “By collaborating with the Leonhardt team on this cutting edge approach, we hope to truly advance cancer treatments by using a common sense approach that is uniquely tailored to an individual patient. The Leonhardt team has a record of bringing breakthrough innovations from concept to market and strong leadership, and we believe with confidence they will do it again with this product.”

“In our work to discover the right bioelectric signals to promote organ regeneration we worked to find protein expressions that promoted cell division on demand and increased blood supply. By serendipity un-intentionally we discovered specific bioelectric signals that immediately halted cell division and halted blood supply. We sent these results into the U.S. patent office to make our first claims for a cancer therapy. In the process of filing our patents we came across the work of the Neuro Code Tech Holdings team led by Eleanor Schuler and found their technology to go a step further in having both a read and write neuro code customization. We are in awe of their inventive genius and feel honored to now be teamed with them,” stated Dr. Jorge Genovese and Howard Leonhardt co-inventors of the Leonhardt Ventures technology platform.

Link to previous related press release:

Leonhardt Ventures and CerebraCell File Patent Application for Treating Cancer Tumors with Bioelectric Stimulation –

The Leonhardt team is also working on bioelectric neuro code signal reading that it believes can be an early detection system for cancers and organ regeneration to follow cancer tumor destruction.

About Leonhardt Ventures:

Leonhardt Ventures founded in 1982 is a leading developer of organ regeneration, support assist and repair technologies. In the 1980’s the Leonhardt team led the development of predictably compliant cardiovascular balloon catheters, in the 1990’s world leadership in patented stent grafts for aneurysm repair and percutaneous heart valves, in the 2000’s Leonhardt has led the way in stem cell and bioelelectric based organ regeneration technologies. The team led the first-in-man non-surgical stem cell repair of a human heart in 2001. Leonhardt Ventures operates innovation/startup accelerators in California and Utah under the name Leonhardt’s Launchpads currently incubating 30 startups and licensable technology platforms. Leonhardt’s Launchpads and it’s startups are supported by over 37 Scientific Advisory Board members and 70+ business mentors – Main web site:

About Neuro Code Tech Holdings LLC:

Neuro Code Tech Holdings (NCTH) is a New Mexico-based company focused on the research, development and intellectual property protection of biolectronic cancer treatment technology. It’s chief scientific officer, Eleanor Schuler, has almost three decades of experience in developing and testing neuro-coded electric signals for providing a diverse spectrum of treatments for human and animal applications.

Corporate Notes: Leonhardt Ventures is Leonhardt Vineyards LLC DBA Leonhardt Ventures a Los Angeles, California LLC (formed in 1982 as sole propreitorship HJ Leonhardt & Co in Minneapolis. and converted to a California LLC in 2005). Leonhardt’s Launchpads is Cal-X Stars Business Accelerator, Inc. DBA Leonhardt’s Launchpads a California C Corporation formed in 2013. Leonhardt’s Launchpads Utah, Inc. is a Utah C corporation formed in November 2015 and officially incorporated in 2016.

Caution Statement: Technologies referenced herein are early stage developments in early feasibility bench top and animal testing phase. Safety and efficacy is not yet proven. No efficacy or safety claims are implied. For potential investors investing in our innovation accelerator or its startups/licensable technology platforms is very high risk due to the early stage of these developments, the high regulatory and development cost to bring products of this type to market, patent lititagion risk, heavy competition and our limited capital on hand and small staff. This type of investment is not suitable to most and is limited in access at this time only to sophisticated accredited investors only with direct long standing experience in these type of investments. Due our small staff and many developments in process not all of our 30+ web sites are up to date and thus information at times may be outdated. If you have any specific questions please email us at

Leonhardt and Genovese file Patent for Bioelectric Controlled Expression of PDGF a Powerful Organ Regeneration Cytokine

Press Release – Salt Lake City, Utah and Los Angeles, CA – December 19, 2016 (PRBUZZ) — Leonhardt’s Launchpads, an organ regeneration focused innovation/startup accelerator, focused on developing novel therapeutics for the treatment of organ degeneration today announced that it has filed a new provisional patent application for the controlled expression of platelet derived growth factor (PDGF). PDGF is a powerful organ regeneration protein. This patent will be sub-licensed exclusively organ by organ to 25 unique organ regeneration focused startups within the Leonhardt led innovation accelerators in Utah and California including BioLeonhardt heart, AortaCell aorta, CerebraCell brain, EyeCell eye, Stem Cell Bra breast and PancreaCell for pancreas regeneration.

“We targeted the discovery search for the precise bioelectric signal for triggering PDGF expression from tissues more than 4 years ago and were delighted to finally hit on it with a highly substantial expression increase with our optimized signal. This adds to our building library of over a dozen bioelectric stimulation signals for promoting organ regeneration. We believe this combined with our programmable micro-infusion pump and fifteen component organ regeneration composition puts our team in a leadership position to in the near future help patients with degenerating and diseased organs to recover.” Dr. Jorge Genovese, VP of Bioelectric Regeneration Research at BioLeonhardt LTP, Cal-X Stars Business Accelerator, Inc. and Leonhardt’s Launchpads Utah, Inc.

The Leonhardt-Genovese team working in collaboration with component suppliers has developed both wireless non-invasive and implantable wire lead based means to get their regeneration and healing promoting bioelectric signals to organs.

Platelet-derived growth factors (PDGF) constitute a family of four gene products (PDGF-A–D) acting by means of two receptor tyrosine kinases, PDGFRα and β. Three of the ligands (PDGF-A, -B, and -C) bind to PDGFRα with high affinity.

PDGF’s Properties for Organ Regeneration:

  • PDGF signaling is essential for epicardial cell proliferation.
  • PDGF PDGF signaling plays important roles in coronary vessel formation.
  • PDGF induces DNA synthesis in cardiomyocytes.
  • PDGF (a protein) recruits stem/progenitor cells.
  • PDGF can trigger controlled cell proliferation.
  • PDGF can contribute to cell reprogramming and transformation into induced multipotent stem cells.
  • PDGF downstream effects include regulation of gene expression and the cell cycle.
  • PDGF can be used to create cell-specific antifibrotic compounds including those needed for liver regeneration.
  • PDGFs are required for normal kidney development via recruitment of mesenchymal cells to both glomeruli and the interstitium.
  • PDGF exerts essential roles from the gastrulation period to adult neuronal maintenance by contributing to the regulation of development of preplacodal progenitors, placodal ectoderm, and neural crest cells to adult neural progenitors, in coordinating with other factors.
  • PDGF plays critical roles for maintenance of many specific cell types in the nervous system together with vascular cells through controlling the blood brain barrier homeostasis.
  • PDGF modulates neuronal excitability through adjusting various ion channels, and affecting synaptic plasticity and function.
  • PDGF stimulates survival signals, majorly PI3-K/Akt pathway but also other ways, rescuing cells from apoptosis.
  • PDGF in dendrite spine morphology is critical for memory in the developing brain.
  • PDGF has been found to stimulate regeneration of peridontal tissues and bone.
  • PDGF has been found to highly stimulate hair regeneration.

“PDGF signaling was found years ago to be essential in regeneration of hearts in animals. Researchers demonstrated that PDGF signaling induces DNA synthesis in the cells and is required for cardiomyocyte proliferation during heart regeneration. We began using PDGF in our biological pacemaker development in the 1990’s and found it worked well to help form new sino atrial node cells from atrial myocytes. PDGF has been found useful in regeneration of other organs such as eyes, lungs, kidneys, brains, hair and aortas. We now have learned to harness the controlled natural release of this super potent regenerative protein via a specific bioelectric stimulation signal.” states Howard Leonhardt, co-Inventor.

“PDGF is one of the most potent growth factors in promoting cell, tissue and organ repair applicable to a wide variety of uses. It has been demonstrated to be especially useful in heart regeneration. We are proud to have extended our portfolio of bioelectrical stimulation signals to include PDGF. We are embarking upon well controlled translation research studies to prove our combination therapy out for regenerative repair of a number of organs.” states Dr. Leslie Miller, Chief Medical Officer of Leonhardt’s Launchpads and BioLeonhardt.

About Leonhardt’s Launchpads:

Operated by Cal-X Stars Business Accelerator, Inc. Leonhardt’s Launchpads was founded in Santa Monica in 2013 and just recently moved to 177 E. Colorado Blvd. in Pasadena, CA. The five year accelerator is incubating 26 regenerative medtech and 4 regenerative economy startups and licensable technology platforms (LTPs).

About Leonhardt’s Launchpads Utah, Inc.:

Founded in November 2015 in Salt Lake City, Utah, just off the campus of the University of Utah, is the World’s First Organ Regeneration Focused Innovation/Startup Accelerator. The company has lab space with a staffed research team at the USTAR BioInnovations Gateway Utah facility at 2500 S. State Street, Salt Lake City, Utah. The accelerator is currently incubating 7 organ regeneration focused startups.

About Leonhardt Ventures (Leonhardt Vineyards LLC DBA Leonhardt Ventures):

Founded in 1982 is the patent holding vehicle and venture capital arm of inventor Howard J. Leonhardt. In the 1980’s Leonhardt developed a market leading cardiovascular balloon catheter, in the 1990’s the leading stent graft system for aortic aneurysm repair and one of the first percutaneous heart valves and biological pacemakers. Since 2000 the focus has been on organ regeneration technologies with a combination of bioelectric signaling and repeat delivery of mixed stem cell + growth factor based compositions. Leonhardt has over 21 U.S. Patents with over 100 issued patent claims and dozens more pending.

About BioLeonhardt:

BioLeonhardt LTP founded in 2013 is the flagship technology platform of Leonhardt Ventures and Leonhardt’s Launchpads Utah, Inc. focused on heart regeneration. BioLeonhardt developed a combination three component system for heart regeneration comprised of (1) a bioelectric stimulator controlling release of regenerating promoting proteins including a stem cell homing factor, (2) an implantable, programmable and re-fillable micro infusion pump and (3) a fifteen component stem cell based heart regeneration composition.

Cautionary Note Regarding Forward-Looking Statements:

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the conduct, size, timing and results of discovery efforts and clinical trials; scope, duration, validity and enforceability of intellectual property rights; plans regarding regulatory filings, future research and clinical trials; plans regarding current and future collaborative activities and the ownership of commercial rights; future royalty streams, and any other statements about Cal-X Stars Business Accelerator, Inc, Leonhardt Vineyards LLC DBA Leonhardt Ventures, or Leonhardt’s Launchpads Utah, Inc. management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact our business are set forth in our 506D part C Cal-X Stars Businesss Accelerator, Inc. private placement memorandum originally filed in 2013 and updated via our Annual Reports. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we assume no obligation to update these forward-looking statements.

Note – Each organ specific web site linked via Leonhardt Ventures has at the bottom or the tope of its landing page a link to supporting scientific articles.

Web Sites:

Leonhardt Ventures – this site includes links to all portfolio startups.
BioLeonhardt LTP
Cal-X Stars Businesss Accelerator, Inc includes links to videos of platform innovations.
Leonhardt’s Launchpads Utah, Inc.

Pancreacell Presents Updated Design For Total Pancreas Regeneration At Chicago Conference

October 19th, 2016 – Chicago, IL – PancreaCell a Leonhardt Ventures Co. incubating in the Leonhardt’s Launchpads Utah organ regeneration innovation accelerator in Salt Lake City, Utah presented today at the Annual Pancreatic Disorders and Treatment Conference in Chicago, IL – its updated design and translational research plan with intention to bring to market the first total pancreas regeneration technology.

The PancreaCell product is a combination device implanted in a patient’s abdomen just below the skin and a proprietary fiteen component stem cell based PC-15 pancreas regeneration composition. It is designed to regenerate a pancreas over a 36 month course of treatment. The device is a bioelectric stimulator the controls expression of over 12 regeneration promoting cytokines combined with a micro infusion pump that has two re-fillable chambers via silcone septums placed just below the skin surface. The programmable micro infusion pump is easily re-filled with a standard syringe and needle at home. The current protocol calls for 2mls of infusion daily of the PC-15 regeneration composition. The stimulator pump is connected to the pancreas via a pacing infusion lead that is affixed to the pancreas with an atraumatic tip. The patented and patent pending bioelectric signal controlled protein expressions include SDF-1, a known stem cell homing signal, IGF-1, HGF, EGF, Activin A+B, eNOS, VEGF, Follistatin, Tropoelastin, TNF A and the team is working on adding GDF-10, GDF-11, BMP-4+7, Serontonin, Neuorgenin 3 as well as other cytokines.

The company shared their translational research plan which starts now with lab testing utilizing the new technology of “organs in a dish” side by side with small animal safety studies. This will be followed by both large animal and donor human pancreas studies. The donor human pancreas will be preserved after harvest with a perfusion system meant to keep the pancreas as “alive” as possible through the testing. The company plan is to follow this with a pilot clinical study focused first on safety with dose escalation in late 2017 or early 2018.

More information may be found on the company’s web site at This includes an introduction animation video – and slide deck – as well as scientific articles that support the rational of the components of the PancreaCell protocol and product –

PancreaCell: Is a startup licensable technology platform (LTP) founded in early 2015 incubating now within the Leonhardt’s Launchpad’s Utah, Inc. organ regeneration innovation accelerator in Salt Lake City, Utah. The company is focused on pancreas regeneration and pancreatic cancer treatment based on its three part technology platform of bioelectric stimulation + micro infusion pump + fifteen component regeneration composition –

Leonhardt’s Launchpad Utah, Inc.: Formed in late 2015 is an innovation and startup incuabor/accelerator focused on organ regeneration with a distinguished and experienced Utah based board of advisors –

Leonhardt Ventures: Formed in 1982 (originally H.J. Leonhardt & Co.) Leonhardt Ventures led the development in the 1980’s of turn key cath labs and CCU’s, predictably compliant cardiovascular balloon catheters and began organ regeneration research utilziing bioelectric energy and stem cells. In 1988 their research team completed the first ever muscle stem cell repair of a damage heart in an animal. In the 1990’s the team developed and patented the world’s leading stent graft for aortic aneurysm repair, an intravascular lung catheter, vibrational energy systems for preventing clot formation and improving gas exchange, the first stem cell delivery catheters, an electro magnetic radiation delivery catheter, one of the first biological pacemakers and the first percutaneous heart valve. In 1999 they launched the first stem cell repair of damaged hearts company. In 2001 they completed the historic first-in-man non-surgical stem cell repair of a human heart in The Netherlands. Since 2001 the team has focused on the development of an organ regeneration platform technology utilizing the combination of bioelectric signal controlled protein expression and micro infusion pump delivery of a proprietary fifteen component regeneration compositions –

CerebraCell Unveils “Brain Saving” Helmet for Rapid Stroke Recovery

bio Unknow2nAugust 5th, 2016 – Santa Monica, CA and Salt Lake City, UT – CerebraCell a Leonhardt Ventures Co. released today that it has filed a provisional patent application for a “brain saving” helmet to help minimize the damage from strokes.  Here is a link to a video demonstration of the technology –  The company envisions that every ambulance will have these devices in the future and they will be stored in airports, planes, malls, stadiums and other high people traffic areas just like portable defibrillators are today.   The CerebraCell “brain saving” helmet is equipped with a bioelectric energy micro stimulator that controls release of 10 key brain regeneration and brain blood flow promoting proteins including SDF-1, a stem cell homing signal and IGF-1 (DNA repair molecule).  The helmet is equipped with bioelectric signal transmitting micro electroacupuncture electrodes that either transcutaneously or percutaneously contacts safely scalp tissue.   A micro infusion pump is included that may be repeatedly loaded with the CCA-15 and/or CCR-15 CerebraCell proprietary fifteen component stem cell based angiogenic and regeneration compositions.  EMT personnel will carry frozen syringes with these compositions pre-loaded and ready to inject just as they do today for rapid clot dissolving drugs.  In stroke management time = brain.  So if this auto programmed helmet can be placed on a stroke victims head as soon as possible after artery blockage and clot dissolving we believe we can preserve much greater amount of brain tissue from the damaging effects of the stroke.  Earlier this week the CerebraCell team announced a joint venture with, the disease management company, to co-develop in partnership with other firms a comprehensive tele-stroke management and recovery program which will include the CerebraCell auto programmed “brain saving” helmet –  This helmet is being designed so that any EMT personnel under the remote tele-conferencing guidance of a physician can apply the “brain saving” therapy within minutes of arrival to the patient’s home or other location of stroke onset. 

CerebraCell is implementing a carefully designed translational study plan with patient safety in mind first.  It is our hope that this product will enter clinical trials in 2017.  The Leonhardt Ventures team that guides CerebraCell has significant experience in implementing organ regeneration and repair clinical studies since the 1980’s. The team completed the first-in-man pioneering percutaneous stent graft aortic aneurysm repair case in 1995 in Melbourne, Australia that led onto pilot, Phase I, Phase II and Phase III studies that have established the Leonhardt patented stent graft still today holding a world leading share of all non-surgical aortic aneurysm repairs.  In early 2001 the team led the historic first-in-man percutaneous muscle stem cell repair of a damaged heart in The Netherlands that led onto successful pilot, Phase I, Phase II and Phase II/III studies.  

About CerebraCell:

CerebraCell formed in 2015 is focused on brain regeneration utilizing bioelectric stimulation and and a re-fillable micro infusion pump that is re-filled daily or weekly with the CCA-15 or CCR-15 angiogenic and regeneration mixed stem cell based compositions.  For more information including supporting scientific articles please visit

About Leonhardt Ventures:

Leonhardt Ventures formed in 1982 as H.J. Leonhardt & Co. pioneered compliant balloon cardiovascular catheters, electrical stimulation for improving blood flow and turn key caths labs in the 1980s, intravascular lung, radiation caths, stem cell delivery systems, stent grafts, percutaneous heart valve and stem cell repair of hearts in the 1990’s.   Since 2000 the team has focused on bioelectric + stem cell based organ regeneration, circulatory assist devices and genomics and high fidelity data based heart failure and stroke management and recovery.  Leonhardt Ventues operates incubators and accelerators in California and Utah to primarily move its own inventions from concept to market as well as a select few from outside its own laboratories.  See for more information. 

Contact:  Howard Leonhardt, email, Leonhardt’s Launchpads Utah, 489E 400 South, Unit 116, Salt Lake City UT or Leonhardt Ventures, 1531 6th Street, Unit 401, Santa Monica, CA  90401

Leonhardt Ventures to Hold Technology Showcase in Conjunction with the 22nd Annual San Diego Heart Failure Symposium

Co-Sponsored by HealthiosXchange 

Saturday June 18, 2016 @ 2pm Estancia Hotel  – To Register email Sofia J. Yepes at and she will send by return email the exact conference room meeting place within the hotel

June 17th, Santa Monica, CA – Leonhardt Ventures will present the following technologies in its showcase.

Click to watch BioLeonhardt introduction VIDEO – – first combination implantable stem cell/growth factor micro pump + bioelectric regeneration stimulator for regenerating hearts will be presented –    BioLeonhardt related Scientific Supporting Articles – 

Leonhardt Ventures Cal-X Stars Accelerator is led by a 40 person Scientific Advisory Board –  and 80 person Business Advisory Board –

BioLeonhardt  –  first implantable, programmable, re-fillable stem cell pump in combination with bioelectric regeneration stimulation for treating advanced heart failure.  Featuring combined utilization of MicroRNAs, time release SDF-1, various growth factors, nutrient hydrogel, cardiac matrix, follistatin, troponelastin, HGH, HGF, IGF-1, EGF, Pyruvate, APO E, Erthropoiten, cardiac stem cells and muscle progenitor stem cells all with programmed repeat deliveries.  Patented bioelectric regeneration stimulator causes controlled release of SDF-1 (stem cell homing signal), IGF-1, EGF, VEGF, eNOS follistatin, troponelastin and HGF from tissues and controls cell proliferation and differentiation. 

MyoStim Peripheral – electrical stimulation device for treating critical limb ischemia and diabetic foot ulcers, pain relief – –  the Axion device is U.S. FDA 510K market cleared for microcurrent treatments – FDA 510(k) K911814.   Data on 47 clinical patients treated with the Wetling (Leonhardt Ventures collaborator) CE Mark approved wireless microcurrent system for treating diabetic foot ulcers in Germany, Switzerland and Denmark will also be presented and well as an introduction to cominbation microcurrent and stem cell + growth factor micro pump healing bandages.

Cardiobridge – – Highest flow rate 10FR circulatory assist catheter pump in clinical testing for acute decompensating heart failure and high-risk PCI.  Data on about 35 clinical patients will be presented with exceptional notable improvement in renal function.  CE Mark application has been filed. 

Bioheart, Inc.* – – Phase III leader in applying adult muscle stem cells to treat advanced heart failure.  Only cell type known to grow new contractile muscle in the depths of scar tissue.  *Leonhardt Ventures founded Bioheart, Inc. in 1999 but now is only a minority position shareholder.  Bioheart MyoCell in Phase II/III clinical trials beat placebo injections by 95.7 meters in exercise capacity improvement.  84% of Bioheart MyoCell treated patients have improved in at least compared to only 16% of placebo or control patients in clinical studies since 2001.

BioPace – world’s first biological pacemaker made entirely of living cells –

CoroStim – world’s first vibrational energy emitting pacemaker that prevents plaque formation and blood clots in high risk coronary arteries, heart chambers, heart valves and devices such as LVADs –

CerebraCell – microcurrent based non-invasive or minimally invasive energy system for brain regeneration.  Also non-invasive cerebral aneurysm repair –

AortaCell – Method and device to treat aortic aneurysms non-invasively and minimally invasively with devices that deliver focal wireless electrical energy to weakened aortic wall tissue that causes reparative autologous stem cells to home to that chosen treatment location which are then differentiated into smooth muscle thus reinforcing vessel wall strength.  Also a new product developed of 2nd beating heart in aorta –

EndoCell – Method and device for growing new endothelium lining of a damaged artery with a percutaneous needle catheter, endothelial progenitor cells, laser light and biolelectric regeneration energy –

Valvublator – Percutaneous catheter device for de-calcifying, cell sodding and regenerating heart valve leaflets so a patient may keep their own valve instead of getting an artificial implant –   + Also tissue engineered heart valves.

HeartScore + NI Medical –  Total Heart Failure Management System, heart failure and cardiovascular genomics, lung water necklace, @ home monitoring, smart phone app and high fidelity noise free ECG analysis – +   HeartScore is also getting ready to publish the Top 100 Cardiovascular Innovations of eMagazine as well.

BioLeonhardt Whole Body – Developing whole body regeneration chamber designed to take 30 years off age and add 30 years extension to life (early stage development).

About Leonhardt Ventures:  Since 1982 Leonhardt Ventures has a strong history of inventing, developing, backing and bringing to market leadership products for treating heart and cardiovascular disease. Over 250,000 patients have been treated to date with Leonhardt inventions.  In the 1980’s the group developed market leadership in patented cardiovascular polyurethane balloon catheters including drug, stem cell and radiation delivery systems, electrical stimulation devices for improving blood flow and also turn-key cath labs.  In the 1990s they developed over 20 additional devices including the first commercially successful stent graft for aortic aneurysm repair (TALENT – Taheri-Leonhardt Stent Graft) – SEE VIDEO, the first percutaneous heart valve, intravascular lung catheter, the Pro-Cell intracavity stem cell delivery system and the MyoCath line of stem cell delivery catheters.  Leonhardt patented inventions – ;-   include the first heart failure pacemaker able to recruit reparative stem cells to damaged heart tissue (MyoStim  Pacers –  In 2001 the team led the first in the world non-surgical case of stem cell repair of damaged heart muscle in a human patient with  Bioheart  MyoCell  .  That led to the first Phase II/III double blinded, randomized, placebo controlled trial for muscle stem cells growing new contractile muscle in post heart attack tissue in advanced heart failure patients – results published in the American Heart Journal Bioheart  MyoCell patients 95.7 meters improvement in exercise capacity over placebo (minus 4 meters decline).  The Leonhardt led team at BioPace is preparing to complete the first ever biological pacemaker implantation made entirely of living cells in a human patient within the next 12-18 months.  For more Leonhardt Ventures information – 1Q 2015 Newsletter and 2014 Annual Report –

About Cal-X Stars Business Accelerator, Inc  Leonhardt Ventures’ organized the Cal-X Stars Business Accelerator, Inc. in 2013 to serve as a 5 year business accelerator for cardiovascular life science and social good impact innovations and startups.   The Cal-X Stars 2015 class portfolio includes 20 regenerative medtech and 15 regenerative economy startups.

About Healthiosxchange:    The HealthiosXchange is the premiere investment marketplace dedicated exclusively to the global healthcare industry.  Employing crowd funding as the cornerstone of a new paradigm in healthcare investing, the HealthiosXchange offers direct access to the broadest investment opportunities on a “Fee Free, Carry Free” basis in the most trusted online environment.  The HealthiosXchange is an affiliate of Healthios Capital Markets, LLC., a FINRA-regulated broker dealer based in Chicago, with offices in Boston, London, Geneva, and Bangkok.  Healthioxchange is a leader in self directed IRA financings with accredited investors into syndicates led by proven track record industry leaders.

Healthiosxchange is the official listing board for the the Cal-X Stars Business Accelerator, Inc. $15 million offering via 506D part C. This exemption allows general solicitation and up to 2000 accredited investors.  Any potential investor’s accredited status must be verified by a broker, lawyer, accountant or other verifiable means.   Cal-X Stars Business Accelerator is incubating/accelerating by charter 15 cardiovascular and 15 social good impact startup innovations with intention to start auctioning them off to the highest bidders starting May 11th, 2018.   By charter Cal-X Stars Business Accelerator, Inc will not accept any self directed IRA investments that exceed 10% of a person’s IRA total portfolio and we recommend 5% due to the very high risk nature of investing in early stage cardiovascular and social good impact startups such as those incubating within the Cal-X Stars accelerator.   Any potential investor should read all risk factors published in our private placement memorandum.

About The 22nd Annual San Diego Heart Failure Symposium:   Offers a unique opportunity to learn about the newest and most exciting innovations in the field. New strategies for patient management are being developed and some of these are on the verge of approval for use in the heart failure population. The sessions for this year’s Symposium include lectures on the best way of managing risk factors for heart failure, where and how new therapies will fit into the picture and the optimal use of devices for detecting and treating heart failure. The faculty for the Symposium is exceptionally strong and includes experts from UCSD as well as guest speakers from Los Angeles, Minneapolis and Boston. Concepts brought up in the lectures will be examined further in panel and case discussions. Most importantly, attendees will have the opportunity to listen to and meet the outstanding faculty that will participate in the 22ndAnnual San Diego Heart Failure Symposium –   Dr. Barry Greenberg the Chair of this conference is a Leonhardt Ventures Scientific Advisory Board member since 2013.

Contact:   Sofia Yepes @, Leonhardt Ventures, 1531 6th Street, Unit 401, Santa Monica, California, 90401

Device to Cut Orthodontic Treatment Time in Half – Leonhardt Ventures and OrthodontiCell File Provisional Patent Application

Santa Monica, CA and Salt Lake City, Utah, April. 20th, 2016 – PRBuzz – Leonhardt Ventures — a developer, manufacturer and marketer of advanced organ regeneration products — has announced the expansion of its intellectual property portfolio via its startup OrthodontiCell.  OrthodontiCell is incubating within Cal-X Stars Business Accelerator, Inc.  The Company has filed a provisional patent application in the U.S. Patent and Trademark Office for inventions relating to bioelectric stimulation controlled release of RANKL and a number of other proteins, including stem cell homing factor SDF-1, designed to accelerate tooth movement and cut in half the time required for orthodontic treatment with braces and clear aligners – the OrthodontiCell Tooth Movement Accelerator TM.  Studies are currently underway in Argentina.

Howard J. Leonhardt the Founder and CEO of Leonhardt, Ventures and Cal-X Stars Business Accelerator, Inc., Dr. John Marchetto an Orthodontist in Weston, Florida and Dr. Jorge Genovese a collaborative researcher from Buenos Aires, Argentina are co-inventors of this product.
“This invention addresses the desire to reduce in half the time it takes to treat orthodontic patients.  The approach is  to speed up the normal process of bone demineralization in order to accelerate tooth movement.  Millions of people that wear braces or aligners would love to cut their treatment time in half.  Other light and vibration devices fall short in providing a clear and reliable pathway to the underlying mechanism of action for tooth movement.  Also, the repeat RANKL needle injection methods are painful for the patients and are needed too frequently.  This invention is completely different than previous devices as it provides clear cut direct control for the release of essential cells and proteins needed for accelerating tooth movement, and with less pain”,  states Dr. John Marchetto, co-Inventor.

The OrthodontiCell team is in the process of launching well-designed studies both in and outside the U.S. to document the safety and efficacy of its Tooth Movement Accelerator TM product.


Howard Leonhardt co-inventor of this device previously patented an electrical stimulation device for recruiting stem cells to damaged organs including the heart by causing the release of SDF-1 stromal derived factor-1 on demand working in collaboration with Dr. Juan Chachques of Paris –  Dr. Genovese has been conducting electrical stimulation based regeneration research for over twenty years with numerous published peer reviewed papers and is co-inventor with Leonhardt on nearly a dozen new patents pending.
Howard Leonhardt presented earlier this year their team’s 27 Year Experience with Stem Cell Therapies for Organ Regeneration and highlighted some of the spin out startup technology platforms that have emerged from the original work on heart regeneration which are now also incubating in the Cal-X Stars Business Accelerator and Leonhardt’s Launchpads –

About Leonhardt Ventures:   Since 1982 Leonhardt Ventures (formerly H.J. Leonhardt & Co.) has been developing and bringing to market cardiovascular products.  Howard Leonhardt founder has 21 issued U.S. patents with over 100 U.S. patent claims and has about a dozen more pending or in process.   Leading past products include the POLY-CATH line of predictably compliant balloon catheters, TALENT stent graft, VALVE STENT percutaneous heart valve, MyoCath and Pro-Cell Stem Cell Delivery Catheters, BioPace biological pacemaker, Stem Cell Bra and the BioLeonhardt micro stimulator and micro pump for heart regeneration –

About Cal-X Stars Business Accelerator, Inc.:   Formed in 2012 Cal-X Stars is a 5 year business accelerator focused on regenerative medtech and regenerative economy startups.   Cal-X Stars Business Accelerator, Inc. helps support and operate Leonhardt’s Launchpads NorCal, CalXelerator, SciAcclerator, Leonhardt’s Launchpads Utah, LABioHub and Startup California –

About OrthodontiCell:  A startup focused on accelerating tooth movement formed in 2015 by Dr. John Marchetto and Howard Leonhardt incubating within the Cal-X Stars Business Accelerator.  A spin out of previously formed DentaCell.

About DentaCell:  A startup focused on reducing pain and accelerating healing of gums after dental procedures and on tooth pulp cold storage for later stem cell retrieval and expansion founded incubating with the Cal-X Stars Business Accelerator –

All capital for OrthodontiCell (a high risk early stage startup) is raised only through Cal-X Stars Business Accelerator, Inc via 506D Part C – SEE RISK FACTORS HERE > limited to accredited and sophisticated investors only or Leonhardt Ventures’s own internal funds at this time.   Leonhardt Ventures and Cal-X Stars Business Accelerator, Inc. are incubating 23 regenerative medtech startups at this time most of them based on the same patented micro stimulator and micro pump combination device pointed to different organs – BioLeonhardt MyoStim = heart, MyoStim Peripheral = limbs, CerebraCell = brain, EyeCell = eye, AortaCell = aortas, PancreaCell = pancreas, Stem Cell Bra = breast, RegenaLung = lungs, HairCell = hair, Valvublator = heart valves, BioPace = biological pacemaker.

Leonhardt Ventures’ Cal-X Stars Business Accelerator is led by over 70 business mentors and team members with substantial industry experience – over 35 scientists and clinicians on our Scientific Advisory Board –

Contact:  OrthodontiCell a Cal-X Stars Business Accelerator, Inc. Startup Technology Platform –  Media Relations Brian Hardy @ or Howard Leonhardt @
This provisional patent application was filed electronically utilizing software.

Safe Harbor
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, which are intended to be covered by the “safe harbor” created by those sections. All statements in this release that are not based on historical fact are “forward looking statements.” These statements may be identified by words such as “estimates,” “anticipates,” “projects,” “plans,” “proposes” or “planned,” “seeks,” “may,” “will,” “expects,” “intends,” “believes,” “should,” “would,” “could” and similar expressions or the negative versions thereof and which also may be identified by their context, such as references to “products under development”. All statements that address operating performance or events or developments that Cal-X Stars Business Accelerator, Inc. or any of its incubating startups such as BioLeonhardt MyoStim, DentalCell or OrthdontiCell, expects or anticipates will occur in the future are forward-looking statements. While management has based any forward looking statements included in this release on its current expectations, we operate in a complex and changing domestic and international competitive environment where new and unanticipated risks may arise, and consequently the information on which such expectations were based, such as expectations of distributor product placements and sales, timing of planned and anticipated product deliveries or product introductions, may change. Forward-looking statements involve inherent very high risks and multiple uncertainties which could cause actual results to differ materially from those in the forward-looking statements as a result of various factors, including those risks and uncertainties described in the Risk Factors and in Management’s Discussion of the Company’s filed Private Placement Memorandum.  We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.  The information shared communicates our intent of direction but does not imply in any form that any required agreements, patents are locked secure in place.  All our incubating startups are under funded and under staffed and we are bootstrapping to make progress with limited resources. We are at even greater risk due to our business plan of bringing multiple startups forward simultaneously with a small core staff spread thin.  Cal-X Stars Business Accelerator, Inc. incubates early stage startups and technology platforms focused on regenerative medtech and regenerative economy innovations.  By nature these early stage startups are high risk investments compounded in risk by requiring many years to get to market through clinical trials and multiple collaborative agreements which are not yet secured.  This investment is only suitable to sophisticated and accredited investors prepared to lose all of their investment understanding clearly the very high risk.

Leonhardt Ventures and CerebraCell File Patent Application for BioElectric Signals to Halt Tumor Growth and Regenerate Organs

– Signals for stopping cell division and halting blood flow to tumors followed by full regeneration program –


Press Release – Santa Monica, CA and Salt Lake City, UT – April 14th, 2016 – Leonhardt Ventures and its spin out startups CerebraCell, PancreaCell, RegenaLung and CancerCell are pleased to announce they have filed a provisional patent application with over 30 patent invention claims with the U.S. Patent and Trademark Office (USPTO) for its first cancer focused therapy comprising signals of halting cell division, stopping blood supply to tumors then followed by a full comprehensive program for organ regeneration.

The patent application is entitled “Treating Cancer Tumors Using BioElectric Stimulation in Combination with Micro Infusion” Inventors Howard J. Leonhardt and Jorge Genovese. This technology is based on bioelectric signals delivered via a micro stimulator device the size of a quarter. The signals may be delivered to target tumors and tissues via non-invasive means via a wearable brain cap or via wireless transmission. When desired a small wire probe may be directed precisely to the tumor and the tissue area targeted for regeneration after cancer treatment. The device may be used as a stimulator alone for small tumors with a small amount of associated organ damage and in combination with a micro infusion pump in cases of large or multiple tumors and significant organ damage in need of regeneration. Although the optimal and desired cancer tumor treatment regime is free of tissue damaging and side effect riddle chemo therapy or radiation it may be used in conjunction with those treatment options when deemed best for the patient by their physician. The regeneration protocol is also predicted to be useful for recovering from these treatment modalities as well and it is hoped that the bioelectric stimulation signaling can reduce the need for chemo or radiation and in many cases eliminate totally the need for these more toxic treatments.

“We do not claim in any way to have an easy instant cure for cancer yet but we are sharing that while we studied organ regeneration targeted bioelectric signals intended to promote controlled cell proliferation and controlled new blood vessel growth we stumbled across signals that seem to promptly stop cell division and blood supply. We decided to file with the USPTO these new inventions with the purpose of stopping cancer tumor growth and combine them our existing portfolio of organ regeneration technologies. The next step will be carefully designed studies to prove out the combination with the hope for complete cancer recovery with less side effects compared to currently available treatments.” states co-inventor Howard J. Leonhardt

“What is unique about this invention is the combination of stopping cell division and stopping blood supply, presumably without toxic side effects found from chemo and radiation treatments, followed by a complete organ regeneration protocol. Other cancer treatments are both toxic and incomplete in fully recovering a patient back to a high quality of life.” states co-inventor Dr. Jorge Genovese “We have high hope for this technology to make a major difference for the better in treating cancer patients and we are on the research path now to prove this out with well controlled studies.” Genovese further states.

Leonhardt-Genovese Patent Abstract

Cytokine + Chemotherapeutic and regenerative treatment for certain cancers may be combined with low intensity, intermediate frequency alternating electric fields that are tuned to release specific beneficial proteins at specific time intervals. More specifically, cell proliferation inhibition and halting blood supply to tumors in the first treatment stage. The bioelectric stimulation treatment may be increased in volume and efficacy by the combination use of an implantable, programmable, re-fillable micro infusion pump that delivers anti-cell proliferation and anti-blood vessel growth proteins as well, if desired, standard cancer treatment drugs such as chemo therapy agents. The second stage of treatment is focused regeneration of cancer damaged tissues back to their most optimal healthy state. The regenerative phase comprises a sequence of recruiting repairative stem cells to the damaged organ by bioelectrically stimulating the the release of SDF-1 (stem cell homing factor), followed by a controlled proliferation signal, a controlled blood vessel supply signal (VEGF) and if desired and useful release of Follistatin, Tropinelastin, Hepatocyte Growth Factor, IGF-1, eNOS and Activin. The stimulation cycle causing release of beneficial proteins for regeneration may be upgraded in volume and speed of delivery by the combination use of an implantable, re-fillable, programmable micro infusion pump for delivering a higher quantity of stem cells, nutrient hydrogel, matrix and other beneficial tissue and organ regeneration promotion proteins.


Cytokine + Chemotherapeutic and regenerative treatment for certain cancers comprising a combination low intensity, intermediate frequency alternating electric fields that are tuned to release particular beneficial proteins in two stages, stage (1) = stopping cancer spread by halting cell proliferation and halting tumor blood supply and stage (2) regenerating the cancer damaged tissue or organ back to optimal health. In many cases, the resulting cell proliferation inhibition is expected to be significantly higher than the inhibition obtained by drug-only regimens of treatment.

A method of killing or inhibiting the growth of cancer cells in a target region followed by regenerating the tissue or organ back to optimal health, the method comprising the steps of:

Stage 1 = Stop cancer tumor growth

applying, to the target region, a series of bioelectric signals that damages the cancer cells or inhibits the growth of the cancer cells via stopping cell proliferation and halting blood supply temporarily, but leaves normal cells in the target region substantially unharmed; and
treating the cancer cells with an other anti-cancer regimen via programmable micro pump infusion, wherein the applying step and the treating step are performed simultaneously.

Stage 2 = Regeneration of post cancer tissue or organ

treating the target region with a series of bioelectric signals to recruit stem cells, grow healthy blood vessels and re-grow healthy functional tissues in the previous cancer damaged region.

Leonhardt Ventures is interested in partnership opportunities for its proprietary technology platform with other biotechnology /pharmaceutical companies. Additionally, CerebraCell, PancreaCell and Regenalung, Leonhardt Ventures spin out startups, are exploring collaboration opportunities with investigators and clinical sites for potential combination treatment options for brain, pancreas and lung cancers indications respectively. The IP portfolio for all other potential cancer treatment indications of use will be housed in a new Leonhardt Ventures spin out startup to be incubated within the Cal-X Stars Business Accelerator, Inc. called CancerCell including breast, skin, prostrate, throat, colon, cervical, throat and esophagus cancers.

Note – CerebraCell is dually incubating in the Cal-X Stars Business Accelerator in Santa Monica and at the University of Northern California Science and Technology Innovation Center in Rohnert Park, CA under the guidance of over 70 business mentors and 35 scientific advisory board members. PancreaCell, RegenaLung and CancerCell are dually incubating in the Cal-X Stars Business Accelerator in Santa Monica and the newly formed Leonhardt’s Launchpads Utah incubator/incubator in Salt Lake City.

About Leonhardt Ventures: Leonhardt Ventures since 1982 (formerly HJ Leonhardt & Co.) has been leading the development of products for treating cardiovascular and heart disease. Operating since 2005 as Leonhardt Vineyards LLC DBA Leonhardt Ventures a California C corporation – In the 1980’s the team led the development of turn-key cardiac cath labs, blood oxygenators, heart valves, electrical stimulation devices for improving blood flow and patented predictably compliant balloon cardiovascular catheters. In the 1990s percutaneous heart valves, stem cell delivery catheters, biological pacing, radiation delivery catheters, intravascular lung, heart valve decalcification, endovascular stent grafts and stem cell repair of hearts. From 2000 forward the primary focus has been on organ regeneration research by the the combination of stem cell delivery, now via a micro pump, and programmed bioelectric stimulation release of specific regeneration proteins led by its flagship startup BioLeonhardt +

About Cal-X Stars Business Accelerator, Inc: Formed in 2012 and incorporated as a C corporation in California in 2013 Cal-X Stars is a 5 year business accelerator focused on regenerative medtech and regenerative economy startups and innovations – Most of the inventions that are the foundation of the startups within the accelerator come from Leonhardt Ventures own associated research centers- Cal-X Stars Business Accelerator, Inc. helps operate and support Cal-Xelerator a 108 day startup launch accelerator, Leonhardt’s Launchapds a life science incubator (founded 2007), Startup California a startup launch assistance resource, LABiohub a life science startup assistance resource focused on the Los Angeles region and Leonhardt’s Launchpads Utah focused on helping launch life science and regenerative economy startups in Utah.

Leonhardt Ventures and the Cal-X Stars Business Accelerator are supported by 35 person Scientific Advisory Board – and a 73 person Business Advisory and Mentorship Board – that help guide all of their associated startups and licensable technology platforms.

Reader Advisory

Statements in this press release may contain forward – looking information. Any statements that are contained in this press release that are not statements of historical fact may be deemed to be forward looking statements. Forward – looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expects” and similar expressions. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward – looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward – looking statements contained in this press release are expressly qualified by this cautionary statement. The forward – looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by securities law. Any investment in Cal-X Stars Business Accelerator, Inc. and its associated startups must be deemed extremely high risk due to the early nature of the research, the high costs to bring products to market in this sector, the undercapitalized and understaffed nature of the business model, the high risk of patent and product liability law suits and a multitude of other risks including lack of single focus of the organization and the use of shared resources not fully controlled by the startups or the accelerator. Investment opportunity is limited to experienced accredited investors only able to bear full loss. Refer to all RISKS found on our investor relations page and links –

Link To Original Story: